CN101896165B - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN101896165B
CN101896165B CN2008801205834A CN200880120583A CN101896165B CN 101896165 B CN101896165 B CN 101896165B CN 2008801205834 A CN2008801205834 A CN 2008801205834A CN 200880120583 A CN200880120583 A CN 200880120583A CN 101896165 B CN101896165 B CN 101896165B
Authority
CN
China
Prior art keywords
suspension
drug substance
particle size
drug
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801205834A
Other languages
English (en)
Chinese (zh)
Other versions
CN101896165A (zh
Inventor
G·穆雷尔
T·基克布施
D·辛格
R·塔库尔
K·沙夫路策尔
N·拉塞纳克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101896165(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101896165A publication Critical patent/CN101896165A/zh
Application granted granted Critical
Publication of CN101896165B publication Critical patent/CN101896165B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
CN2008801205834A 2007-12-13 2008-12-11 有机化合物 Expired - Fee Related CN101896165B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123165 2007-12-13
EP07123165.8 2007-12-13
PCT/EP2008/067364 WO2009074666A1 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (2)

Publication Number Publication Date
CN101896165A CN101896165A (zh) 2010-11-24
CN101896165B true CN101896165B (zh) 2013-07-17

Family

ID=39387173

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801205834A Expired - Fee Related CN101896165B (zh) 2007-12-13 2008-12-11 有机化合物

Country Status (13)

Country Link
US (1) US20100266696A1 (enExample)
EP (1) EP2229148B1 (enExample)
JP (1) JP2011506400A (enExample)
KR (1) KR20100095587A (enExample)
CN (1) CN101896165B (enExample)
AU (1) AU2008334547B2 (enExample)
BR (1) BRPI0820745A2 (enExample)
CA (1) CA2707594C (enExample)
ES (1) ES2460576T3 (enExample)
PL (1) PL2229148T3 (enExample)
PT (1) PT2229148E (enExample)
RU (1) RU2496479C2 (enExample)
WO (1) WO2009074666A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
ES2612257T3 (es) * 2011-05-03 2017-05-16 Chiesi Farmaceutici S.P.A. Formulación de suspensión mejorada de dipropionato de beclometasona para administración mediante inhalación
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT107433B (pt) * 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
SI3191081T1 (sl) 2014-09-09 2020-07-31 Vectura Limited Formulacija, ki vsebuje glikopirolat, postopek in naprava
CN106749008A (zh) * 2015-11-23 2017-05-31 北京九和药业有限公司 一种马来酸茚达特罗的微粉化方法及其应用
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
WO2018019803A1 (en) 2016-07-29 2018-02-01 Laboratorios Lesvi, S.L. Particle size stabilization process
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021216577A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000199A1 (en) * 2000-06-29 2002-01-03 Glaxo Group Limited Novel process for preparing and harvesting crystalline particles
CN1335766A (zh) * 1998-11-03 2002-02-13 奇斯药制品公司 一种制备用于吸入给药的药物颗粒悬浮体的方法
EP1449528A1 (en) * 2000-04-07 2004-08-25 Arakis Limited Treatment of respiratory diseases
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
CN1735403A (zh) * 2002-12-18 2006-02-15 奇斯药制品公司 用于吸入的含有微粒化结晶活性组分的无菌含水悬浮液的制备
CN1964700A (zh) * 2004-04-30 2007-05-16 维克特拉有限公司 药物组合物
EP1834624A1 (en) * 2005-01-07 2007-09-19 Eisai R&D Management Co., Ltd. Medicinal composition and process for producing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US8048451B2 (en) * 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
WO2007024183A1 (en) * 2005-08-26 2007-03-01 Astrazeneca Ab A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1335766A (zh) * 1998-11-03 2002-02-13 奇斯药制品公司 一种制备用于吸入给药的药物颗粒悬浮体的方法
EP1449528A1 (en) * 2000-04-07 2004-08-25 Arakis Limited Treatment of respiratory diseases
WO2002000199A1 (en) * 2000-06-29 2002-01-03 Glaxo Group Limited Novel process for preparing and harvesting crystalline particles
CN1735403A (zh) * 2002-12-18 2006-02-15 奇斯药制品公司 用于吸入的含有微粒化结晶活性组分的无菌含水悬浮液的制备
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
CN1964700A (zh) * 2004-04-30 2007-05-16 维克特拉有限公司 药物组合物
EP1834624A1 (en) * 2005-01-07 2007-09-19 Eisai R&D Management Co., Ltd. Medicinal composition and process for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.Hecq.《Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine》.《journal of pharmaceutics》.2005,(第299期),第169页左栏第1段. *

Also Published As

Publication number Publication date
BRPI0820745A2 (pt) 2015-06-16
WO2009074666A1 (en) 2009-06-18
EP2229148B1 (en) 2014-03-05
CA2707594A1 (en) 2009-06-18
RU2010128248A (ru) 2012-01-20
PL2229148T3 (pl) 2014-08-29
US20100266696A1 (en) 2010-10-21
EP2229148A1 (en) 2010-09-22
KR20100095587A (ko) 2010-08-31
AU2008334547B2 (en) 2011-06-30
JP2011506400A (ja) 2011-03-03
CN101896165A (zh) 2010-11-24
ES2460576T3 (es) 2014-05-13
AU2008334547A1 (en) 2009-06-18
CA2707594C (en) 2015-08-18
RU2496479C2 (ru) 2013-10-27
PT2229148E (pt) 2014-05-26

Similar Documents

Publication Publication Date Title
CN101896165B (zh) 有机化合物
US8512753B2 (en) Micronized particles of low-dosage strength active agents for powder formulations for inhalation
CN1942172B (zh) 用于干粉吸入器的包含低剂量强力活性成分的药物剂型
CN101443018A (zh) 灭菌纳米微粒糖皮质激素制剂
CN101896162B (zh) 有机化合物
MX2013008796A (es) Formulaciones de particulas en polvo seco que contienen dos o mas ingredientes activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vias respiratorias.
US9889094B2 (en) Particle size reduction of an antimuscarinic compound
CN105188757A (zh) 多孔载体颗粒和微粒化药物的可吸入团聚物
JP2008533174A (ja) ナノ粒子ロイコトリエン受容体拮抗薬／副腎皮質ステロイド製剤
CN104470503A (zh) 聚集粒子
CN108463213B (zh) 可吸入扎鲁司特颗粒的制备
CN105209013A (zh) 喷雾干燥制剂经喷雾混合的脱非晶化
US20100269825A1 (en) Inhalation particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone and a corticosteroid
CN113476429A (zh) 包含抗胆碱能药物、皮质类固醇和β-肾上腺素能药物的组合的吸入颗粒
KR102637303B1 (ko) 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
CN119656140A (zh) 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
CN112469443B (zh) 用于吸入用干粉制剂的新型载体颗粒
HK40050575A (en) Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
RU2629085C2 (ru) Кристаллические микрочастицы бета-агониста, покрытые жирной кислотой
HK40037203B (zh) 用於吸入用干粉制剂的新型载体颗粒
CN108633257A (zh) 通过流体动力学空化制备抗毒蕈碱化合物的微粉化颗粒的方法
HK1232434A1 (en) Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
JP2012524817A (ja) 標的粒子サイズを有する、活性医薬を含む凝集体配合物
HK1216302B (zh) 抗毒蕈硷化合物的粒度减小

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130717

Termination date: 20171211

CF01 Termination of patent right due to non-payment of annual fee